HNSBF News and Press, Hansa Biopharma AB From 02/03/22

The following slide deck was published by Hansa Biopharma AB (publ) in conjunction with their 2021 Q4 earnings call. For further details see: Hansa Biopharma AB (publ) 2021 Q4 - Results - Earnings Call Presentation

Hansa Biopharma press release (OTC:HNSBF): Q4 GAAP EPS of -SEK 3.67. Revenue of SEK 15.4M (+305.3% Y/Y). Cash position of SEK 889M at the end of Dec., expected to fund Hansa’s operations into 2023. For further details see: Hansa Biopharma reports Q4 results

Hansa Biopharma provides business update including certain key financials PR Newswire LUND, Sweden , Jan. 9, 2022 /PRNewswire/ -- Commercial launch and market access efforts in Europe progressing as planned; New multiregional commercialization partner...

Hansa Biopharma enters into agreement with AskBio to evaluate feasibility of imlifidase as pre-treatment ahead of gene therapy in Pompe disease Collaboration to evaluate imlifidase as potential pre-treatment prior to the administration of gene therapy in Pompe disease for patien...

Hansa Biopharma AB (publ) (HNSBF) Q3 2021 Earnings Conference Call October 21, 2021, 08:00 AM ET Company Participants Klaus Sindahl - Head of Investor Relations Søren Tulstrup - President & Chief Executive Officer Donato Spota - Chief Financial Officer Conference Call Participants Ch...

ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Recent Strategy outperformance has been broad-based, led ...

Hansa Biopharma to host conference call to provide interim results for first half 2021 and Business Update PR Newswire LUND, Sweden , July 1, 2021 /PRNewswire/ -- Hansa Biopharma AB (Nasdaq Stockholm: HNSA) will publish its interim report for January- June 2021...

Hansa Biopharma publishes Annual Report 2020 PR Newswire LUND, Sweden , April 8, 2021 /PRNewswire/ -- Hansa Biopharma AB "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced the release of the Annual ...

argenx (ARGX) and Hansa Biopharma (HNSBF) have inked a preclinical research agreement for immunoglobulin G (IgG)-modulating technologies.The companies will look at combining imlifidase, Hansa's IgG antibody-cleaving enzyme, and efgartigimod, argenx's FcRn antagonist, which could be used for t...

Hansa Biopharma appoints Dr. Magnus Korsgren as Head of Research & Development Hansa Biopharma appoints Dr. Magnus Korsgren as Head of Research & Development Dr Korsgren to lead the research and development of Hansa's proprietary enzyme technology platform as the Com...